Centogene (NASDAQ:CNTG – Get Rating) had its price objective lowered by stock analysts at SVB Leerink from $10.00 to $6.00 in a research report issued to clients and investors on Monday, Stock Target Advisor reports. The firm presently has an "outperform" rating on the stock. SVB Leerink's price objective suggests a potential upside of 172.73% from the stock's previous close.

Centogene Trading Up 0.9 %

NASDAQ:CNTG opened at $2.20 on Monday. The firm has a market cap of $43.69 million, a PE ratio of -0.91 and a beta of -0.95. The stock has a fifty day moving average price of $2.61 and a 200 day moving average price of $3.58. Centogene has a 12-month low of $1.83 and a 12-month high of $11.75.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Centogene stock. DekaBank Deutsche Girozentrale purchased a new stake in Centogene (NASDAQ:CNTG – Get Rating) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,319 shares of the company's stock, valued at approximately $67,000. DekaBank Deutsche Girozentrale owned approximately 0.08% of Centogene at the end of the most recent reporting period.

Centogene Company Profile

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.

Further Reading

• Get a free copy of the StockNews.com research report on Centogene (CNTG)
• Financial services firm Block stock has fallen (-59%) in 2022
• Hold Pfizer Today With Catalysts for Further Growth Tomorrow
• NVIDIA Stock is a Winding Up for a Record Setting Second Half
• Johnson & Johnson Continues to Prove its Value in a Volatile Year
• MarketBeat: Week in Review 7/11 – 7/15

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.